Inactive Instrument

Bachem Holding AG Share Price Swiss Exchange

Equities

BANB

CH0012530207

Biotechnology & Medical Research

Financials

Sales 2024 * 620M 684M 54.63B Sales 2025 * 811M 894M 71.47B Capitalization 6.25B 6.89B 551B
Net income 2024 * 127M 140M 11.19B Net income 2025 * 160M 176M 14.1B EV / Sales 2024 * 9.98 x
Net cash position 2024 * 64.89M 71.55M 5.72B Net Debt 2025 * 74.85M 82.53M 6.6B EV / Sales 2025 * 7.8 x
P/E ratio 2024 *
52 x
P/E ratio 2025 *
39.4 x
Employees 2,006
Yield 2024 *
1.03%
Yield 2025 *
1.12%
Free-Float 94.31%
More Fundamentals * Assessed data
Dynamic Chart
Managers TitleAgeSince
Chief Executive Officer 56 31/12/18
Director of Finance/CFO 47 31/01/21
Chief Tech/Sci/R&D Officer - 31/12/02
Members of the board TitleAgeSince
Director/Board Member 82 -
Chairman 68 24/04/12
Director/Board Member 51 12/04/11
More insiders
Bachem Holding AG is a Switzerland-based biochemical company that provides services to the pharmaceutical and biotechnology industry. The Company focuses on the process development and manufacturing of peptides and organic molecules as active pharmaceutical ingredients (APIs), as well as on the development of biochemical products for research purposes. Its product portfolio comprises fluorescent dyes for the fluorescence energy transfer (FRET) analysis of receptor-ligand interactions, protein-protein interactions and the cleavage of substrate molecules, as well as glycosylated peptides for the manipulation of drug properties. The Company markets products under the Bachem and Clinalfa brands and operates production facilities in Switzerland and in the United States.
Calendar
More about the company